Salivary Gland-Based Gene Therapy for Lysosomal Storage Diseases

基于唾液腺的溶酶体贮积病基因治疗

基本信息

项目摘要

Recent studies have demonstrated that an intrinsic endocrine pathway is present in salivary glands, distinct from the classical exocrine pathway whereby digestive enzymes are produced and secreted into the saliva by the salivary glands under normal physiological conditions. As such, this distinct endocrine pathway has recently been shown to be capable of robust synthesis and secretion of non-regulated (i.e. constitutive) gene products into the vascular space as a result of retroductal administration of a gene therapy vector. Fabry disease is a member of the family of lysosomal storage diseases, a group of monogenic disorders characterized by deficiency or lack of a class of enzymes (e.g. alpha-Galactosidase A in Fabry disease) involved in intra-lysosomal catabolism of macromolecules. An interesting feature of these diseases is the observation that tissues lacking the specific lysosomal enzyme implicated in the disease are capable of uptake of the specific lysosomal enzyme from the vascular space. This physiology has led to the proposal and subsequent validation of "Enzyme Replacement Therapy" wherein the missing enzyme is produced syntheically and infused intravenously to Fabry patients, resulting in a mitigation of disease symptoms. We seek to combine these emergent technologies into a salivary gland-based gene therapy strategy for Fabry disease in highly relevant mouse knockout model, namely B6;129-Gla(tm1/Kul/J), an alpha- Galactosidase A (-/O) model. We seek to test the hypothesis that an AAV vector containing the sequence for human alpha-Gal A delivered to the salivary glands in alpha-Gal A deficient "Fabry" mice will result in systemic replacement of the enzyme and reversal of the specific systemic biochemical defect underlying Fabry disease. Our specific aims involve: 1) delivery of an alpha-Gal A containing vector to the salivary glands of Fabry mice and biochemical testing of systemic delivery of the enzyme, 2) careful examination of the organ biodistribution of the enzyme, and 3) optimization of dosing and immune physiology to achieve long-term expression of the enzyme. These studies will produce important insights into the technical paramaters of this system, including: longevity of transgene expression, host immune response, and mitigation of Fabry-associated pathology, and form the basis whereby other systemic disorders could be addressed using salivary glands as the biosynthetic site for systemic therapeutics.
近年来的研究表明,唾液腺中存在一种独特的内在内分泌途径

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael J. Passineau其他文献

Michael J. Passineau的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael J. Passineau', 18)}}的其他基金

Ultrasound-Assisted AQP1 Gene Therapy for Functional Restoration of Salivary Glan
超声辅助 AQP1 基因治疗唾液腺功能恢复
  • 批准号:
    8390748
  • 财政年份:
    2012
  • 资助金额:
    $ 24.9万
  • 项目类别:
Ultrasound-Assisted AQP1 Gene Therapy for Functional Restoration of Salivary Glan
超声辅助 AQP1 基因治疗唾液腺功能恢复
  • 批准号:
    8514570
  • 财政年份:
    2012
  • 资助金额:
    $ 24.9万
  • 项目类别:
Ultrasound-Assisted AQP1 Gene Therapy for Functional Restoration of Salivary Glan
超声辅助 AQP1 基因治疗唾液腺功能恢复
  • 批准号:
    8668774
  • 财政年份:
    2012
  • 资助金额:
    $ 24.9万
  • 项目类别:
Ultrasound-Assisted AQP1 Gene Therapy for Functional Restoration of Salivary Glan
超声辅助 AQP1 基因治疗唾液腺功能恢复
  • 批准号:
    8878038
  • 财政年份:
    2012
  • 资助金额:
    $ 24.9万
  • 项目类别:
Ultrasound-Assisted Gene Transfer of Anti-Biofilm Peptides to the Salivary Gland
超声辅助将抗生物膜肽基因转移至唾液腺
  • 批准号:
    8225139
  • 财政年份:
    2011
  • 资助金额:
    $ 24.9万
  • 项目类别:
Ultrasound-Assisted Gene Transfer of Anti-Biofilm Peptides to the Salivary Gland
超声辅助将抗生物膜肽基因转移至唾液腺
  • 批准号:
    8041732
  • 财政年份:
    2011
  • 资助金额:
    $ 24.9万
  • 项目类别:
Salivary Gland-Based Gene Therapy for Lysosomal Storage Diseases
基于唾液腺的溶酶体贮积病基因治疗
  • 批准号:
    7814758
  • 财政年份:
    2009
  • 资助金额:
    $ 24.9万
  • 项目类别:
Salivary Gland-Based Gene Therapy for Lysosomal Storage Diseases
基于唾液腺的溶酶体贮积病基因治疗
  • 批准号:
    7848134
  • 财政年份:
    2008
  • 资助金额:
    $ 24.9万
  • 项目类别:
Salivary Gland-Based Gene Therapy for Lysosomal Storage Diseases
基于唾液腺的溶酶体贮积病基因治疗
  • 批准号:
    7616605
  • 财政年份:
    2008
  • 资助金额:
    $ 24.9万
  • 项目类别:
Salivary gland-based gene therapy for lysosomal storage diseases
基于唾液腺的溶酶体贮积病基因治疗
  • 批准号:
    7244947
  • 财政年份:
    2007
  • 资助金额:
    $ 24.9万
  • 项目类别:

相似海外基金

prediction of the clinical phenotype bye structural modeling of mutant alpha-galactosidase
通过突变α-半乳糖苷酶的结构模型预测临床表型
  • 批准号:
    17K10058
  • 财政年份:
    2017
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The biokinetics of the enzyme by a novel alpha-galactosidase gene mutation in Fabry disease
法布里病中新型α-半乳糖苷酶基因突变引起的酶的生物动力学
  • 批准号:
    17K09514
  • 财政年份:
    2017
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Alpha-Galactosidase A: a novel target for reducing alpha-synuclein toxicity
α-半乳糖苷酶 A:降低 α-突触核蛋白毒性的新靶点
  • 批准号:
    9180234
  • 财政年份:
    2016
  • 资助金额:
    $ 24.9万
  • 项目类别:
Alpha-Galactosidase A: a novel target for reducing alpha-synuclein toxicity
α-半乳糖苷酶 A:降低 α-突触核蛋白毒性的新靶点
  • 批准号:
    9318583
  • 财政年份:
    2016
  • 资助金额:
    $ 24.9万
  • 项目类别:
Safety and efficacy of recombinant human alpha-galactosidase A
重组人α-半乳糖苷酶A的安全性和有效性
  • 批准号:
    7043553
  • 财政年份:
    2004
  • 资助金额:
    $ 24.9万
  • 项目类别:
An Open Label Extension Study of Recombinant Human Alpha-Galactosidase Therap...
重组人 α-半乳糖苷酶疗法的开放标签延伸研究...
  • 批准号:
    7044833
  • 财政年份:
    2004
  • 资助金额:
    $ 24.9万
  • 项目类别:
PRODUCTION OF ALPHA-GALACTOSIDASE A--TRANSFECTED PLANTS
α-半乳糖苷酶 A 的生产——转染植物
  • 批准号:
    2422447
  • 财政年份:
    1997
  • 资助金额:
    $ 24.9万
  • 项目类别:
BIOCHEMISTRY OF HUMAN ALPHA-GALACTOSIDASE A
人类 α-半乳糖苷酶 A 的生物化学
  • 批准号:
    3235585
  • 财政年份:
    1986
  • 资助金额:
    $ 24.9万
  • 项目类别:
BIOCHEMISTRY OF HUMAN ALPHA-GALACTOSIDASE A
人类 α-半乳糖苷酶 A 的生物化学
  • 批准号:
    3235587
  • 财政年份:
    1986
  • 资助金额:
    $ 24.9万
  • 项目类别:
BIOCHEMISTRY OF HUMAN ALPHA-GALACTOSIDASE A
人类 α-半乳糖苷酶 A 的生物化学
  • 批准号:
    3235588
  • 财政年份:
    1986
  • 资助金额:
    $ 24.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了